This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.
The treatments recommended by NICE are Roche’s RoActemra (tocilizumab) and Eli Lilly’s Olumiant (baricitinib), both indicated for use in a hospitalised setting in patients requiring supplemental oxygen, as well
Eli Lilly and Incyte’s Olumiant (baricitinib) was also approved for emergency use in the US in May 2022, making it the first FDA-approved Janus kinase inhibitor for the treatment
This included final results from a clinical trial of Xeljanz (tofacitinib), as well as preliminary findings from an observational study involving Olumiant (baricitinib). ... This includes Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib
In May, Eli Lilly and Incyte were granted FDA approval for their COVID-19 therapy, Olumiant (baricitinib), for the treatment of hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical
In May, Eli Lilly and Incyte were granted FDA approval for their COVID-19 therapy Olumiant (baricitinib) for the treatment of hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical
The double-blind, placebo-controlled trials enrolled 1, 200 patients with severe AA and were randomised to receive a once-daily dose of Olumiant 2mg, Olumiant 4mg or placebo. ... Eli Lilly anticipates that regulatory decisions will be made for Olumiant
More from news
Approximately 10 fully matching, plus 36 partially matching documents found.
Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year. ... Today – more than three years after its NICE TA – Olumiant is finally approaching full implementation.
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...